Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets Oct 30, 2013 Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC) Oct 24, 2013 Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day Oct 08, 2013 Nektar to Host Investor and Analyst R&D Day in New York City Oct 02, 2013 Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol Sep 30, 2013 Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee Sep 26, 2013 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013 Aug 08, 2013 Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets Aug 01, 2013 Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer Jul 30, 2013 Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence Jun 19, 2013 Pagination First page « first Previous page ‹ previous … Page 26 Page 27 Page 28 Page 29 Current page 30 Page 31 Page 32 Page 33 Page 34 … Next page next › Last page last »